
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Vaccine Mandates During COVID-19 Did Not Raise Vaccination Rates, New Study Finds
2
FDA Approves Reformulated Ranitidine After 5-Year Absence
3
Navigating Migraine Management and the Role of Symbravo in Acute Treatment
4
FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Muscle-Invasive Bladder Cancer
5
























































































































































































































